Asmall subset (5% to 10%) of DLBCL cases show positivity for CD5 and areassociated with poor prognosis, whereas CD30 antigen, seen in up to 10% ofcases, may be a useful target for therapy. Here, CD5 is linked to diffuse large B-cell lymphoma.